Cargando…
Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
BACKGROUND: Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits. METHODS: Patients with advRCC and multiple poor-prognostic factors were randomly assigned to receive 25 mg intravenous temsirolimus...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869160/ https://www.ncbi.nlm.nih.gov/pubmed/20461090 http://dx.doi.org/10.1038/sj.bjc.6605647 |